Title:
A HCK INHIBITOR AND A BCL-2 INHIBITOR FOR TREATING ACUTE MYELOID LEUKEMIA
Document Type and Number:
WIPO Patent Application WO/2018/052120
Kind Code:
A1
Abstract:
This invention relates to compounds, compositions and methods for treating leukemia, such as acute myeloid leukemia, in subjects where one or more mutations in FLT3 kinase are present.
More Like This:
Inventors:
ISHIKAWA FUMIHIKO (JP)
SAITO YORIKO (JP)
SAITO YORIKO (JP)
Application Number:
PCT/JP2017/033482
Publication Date:
March 22, 2018
Filing Date:
September 15, 2017
Export Citation:
Assignee:
RIKEN (JP)
International Classes:
A61K45/00; A61K31/4709; A61K31/4985; A61K31/519; A61K31/55; A61K31/713; A61K45/06; A61P35/02
Domestic Patent References:
WO2014017659A1 | 2014-01-30 | |||
WO2014017659A1 | 2014-01-30 |
Other References:
KE JIYUAN ET AL: "Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth", MOLECULAR CANCER, BIOMED CENTRAL, LONDON, GB, vol. 8, no. 1, 31 December 2009 (2009-12-31), pages 132, XP021067956, ISSN: 1476-4598
JOS E VZQUEZ-FRANCO ET AL: "Src, Akt, NF-B, BCL-2 and c-IAP1 may be involved in an anti-apoptotic effect in patients with BCR-ABL positive and BCR-ABL negative acute lymphoblastic leukemia", LEUKEMIA RESEARCH, NEW YORK,NY, US, vol. 36, no. 7, 25 March 2012 (2012-03-25), pages 862 - 867, XP028506946, ISSN: 0145-2126, [retrieved on 20120330], DOI: 10.1016/J.LEUKRES.2012.03.020
SAKUMA: "ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis", ONCOLOGY REPORTS, vol. 25, no. 3, 1 March 2011 (2011-03-01), XP055424985, ISSN: 1021-335X, DOI: 10.3892/or.2010.1123
BAJWA N ET AL: "Inhibitors of the anti-apoptotic Bcl-2 proteins: A patent review", EXPERT OPINION ON THERAPEUTIC PATE, INFORMA HEALTHCARE, GB, vol. 22, no. 1, 1 January 2012 (2012-01-01), pages 37 - 55, XP009172096, ISSN: 1354-3776, DOI: 10.1517/13543776.2012.644274
ANDERSON ET AL., SEMINARS IN HEMATOLOGY, vol. 51, 2014, pages 219 - 227
BAJWA ET AL., EXPERT OPIN THER. PAT., vol. 22, 2012, pages 37 - 55
OLTERSDORF, T. ET AL., NATURE, vol. 435, 2005, pages 677 - 681
TSE, C. ET AL., CANCER RESEARCH, vol. 68, 2008, pages 3421 - 3428
SOUERS, A. J. ET AL., NATURE MEDICINE, vol. 19, 2013, pages 202 - 208
NGUYEN, M. ET AL., PNAS, vol. 104, 2007, pages 19512 - 19517
ZHANG, A. ET AL., INT'L J. CANCER, vol. 128, 2011, pages 1724 - 1735
WEI, J. ET AL., J. MED. CHEM., vol. 52, 2009, pages 4511 - 4523
"Handbook of Clinical Drug Data", 2002, MCGRAW-HILL
"Principles of Drug Action", 1990, CHURCHILL LIVINGSTON
"Basic and Clinical Pharmacology", 2003, MCGRAW HILL
"The Pharmacological Basis of Therapeutics", 2001, MCGRAW HILL
"Remington's Pharmaceutical Sciences", 2000, LIPPINCOTT WILLIAMS & WILKINS.
MARTINDALE: "The Extra Pharmacopoeia", 1999, THE PHARMACEUTICAL PRESS
BERGE ET AL.: "pharmaceutically acceptable salts", J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
SHULTZ LD ET AL., J IMMUNOL, 2005
ISHIKAWA F ET AL., BLOOD, 2005
SOUERS AJ ET AL., NATURE MEDICINE, 2013
PAN R ET AL., CANCER DISCOVERY, 2014
JOS E VZQUEZ-FRANCO ET AL: "Src, Akt, NF-B, BCL-2 and c-IAP1 may be involved in an anti-apoptotic effect in patients with BCR-ABL positive and BCR-ABL negative acute lymphoblastic leukemia", LEUKEMIA RESEARCH, NEW YORK,NY, US, vol. 36, no. 7, 25 March 2012 (2012-03-25), pages 862 - 867, XP028506946, ISSN: 0145-2126, [retrieved on 20120330], DOI: 10.1016/J.LEUKRES.2012.03.020
SAKUMA: "ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis", ONCOLOGY REPORTS, vol. 25, no. 3, 1 March 2011 (2011-03-01), XP055424985, ISSN: 1021-335X, DOI: 10.3892/or.2010.1123
BAJWA N ET AL: "Inhibitors of the anti-apoptotic Bcl-2 proteins: A patent review", EXPERT OPINION ON THERAPEUTIC PATE, INFORMA HEALTHCARE, GB, vol. 22, no. 1, 1 January 2012 (2012-01-01), pages 37 - 55, XP009172096, ISSN: 1354-3776, DOI: 10.1517/13543776.2012.644274
ANDERSON ET AL., SEMINARS IN HEMATOLOGY, vol. 51, 2014, pages 219 - 227
BAJWA ET AL., EXPERT OPIN THER. PAT., vol. 22, 2012, pages 37 - 55
OLTERSDORF, T. ET AL., NATURE, vol. 435, 2005, pages 677 - 681
TSE, C. ET AL., CANCER RESEARCH, vol. 68, 2008, pages 3421 - 3428
SOUERS, A. J. ET AL., NATURE MEDICINE, vol. 19, 2013, pages 202 - 208
NGUYEN, M. ET AL., PNAS, vol. 104, 2007, pages 19512 - 19517
ZHANG, A. ET AL., INT'L J. CANCER, vol. 128, 2011, pages 1724 - 1735
WEI, J. ET AL., J. MED. CHEM., vol. 52, 2009, pages 4511 - 4523
"Handbook of Clinical Drug Data", 2002, MCGRAW-HILL
"Principles of Drug Action", 1990, CHURCHILL LIVINGSTON
"Basic and Clinical Pharmacology", 2003, MCGRAW HILL
"The Pharmacological Basis of Therapeutics", 2001, MCGRAW HILL
"Remington's Pharmaceutical Sciences", 2000, LIPPINCOTT WILLIAMS & WILKINS.
MARTINDALE: "The Extra Pharmacopoeia", 1999, THE PHARMACEUTICAL PRESS
BERGE ET AL.: "pharmaceutically acceptable salts", J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
SHULTZ LD ET AL., J IMMUNOL, 2005
ISHIKAWA F ET AL., BLOOD, 2005
SOUERS AJ ET AL., NATURE MEDICINE, 2013
PAN R ET AL., CANCER DISCOVERY, 2014
Attorney, Agent or Firm:
HIRAKI & ASSOCIATES (JP)
Download PDF:
Previous Patent: HETEROCYCLIC COMPOUND, AND HARMFUL-ARTHROPOD-CONTROLLING AGENT CONTAINING SAME
Next Patent: MEDICAL DEVICE
Next Patent: MEDICAL DEVICE